Cargando…
Novel DNA targeted therapies for head and neck cancers: clinical potential and biomarkers
Head and neck squamous cell carcinoma is the sixth most common cancer worldwide and despite advances in treatment over the last years, there is still a relapse rate of 50%. New therapeutic agents are awaited to increase the survival of patients. DNA repair targeted agents in combination with standar...
Autores principales: | Glorieux, Mary, Dok, Rüveyda, Nuyts, Sandra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655317/ https://www.ncbi.nlm.nih.gov/pubmed/29113422 http://dx.doi.org/10.18632/oncotarget.20953 |
Ejemplares similares
-
The influence of PI3K inhibition on the radiotherapy response of head and neck cancer cells
por: Glorieux, Mary, et al.
Publicado: (2020) -
Effect of ATR Inhibition in RT Response of HPV-Negative and HPV-Positive Head and Neck Cancers
por: Dok, Rüveyda, et al.
Publicado: (2021) -
Dual role for p16 in the metastasis process of HPV positive head and neck cancers
por: Dok, Rüveyda, et al.
Publicado: (2017) -
Radiosensitization approaches for HPV‐positive and HPV‐negative head and neck squamous carcinomas
por: Dok, Rüveyda, et al.
Publicado: (2019) -
HPV Positive Head and Neck Cancers: Molecular Pathogenesis and Evolving Treatment Strategies
por: Dok, Rüveyda, et al.
Publicado: (2016)